Ketotifen Fumarate

DRUG3 trials

Sponsors

Tanabe Pharma Corporation, McGill University Health Centre/Research Institute of the McGill University Health Centre, Peking University Third Hospital

Conditions

AtopicDermatitisST-segment Elevation Myocardial Infarction (STEMI)Widespread Chronic Pain

Phase 3

A Confirmatory Study of TAU-284 in Pediatric Patients With Atopic Dermatitis

CompletedNCT01840605

Tanabe Pharma CorporationAtopic, Dermatitis

Start: 2013-03-31End: 2013-11-30Updated: 2026-01-08

Chronic Widespread Pain and White Blood Cell Activation

CompletedNCT02984397

McGill University Health Centre/Research Institute of the McGill University Health CentreWidespread Chronic Pain

Start: 2016-12-31End: 2020-01-31Updated: 2020-02-20

Phase 4

The Efficacy and Safety of Ketotifen in Primary PCI Patients With STEMI

Peking University Third HospitalST-segment Elevation Myocardial Infarction (STEMI)

Start: 2022-09-01End: 2024-12-31Target: 60Updated: 2022-08-23

Related Papers

Tryptase as a Biomarker for Adverse Prognosis in ST-Segment Elevation Myocardial Infarction Patients: A Prospective Cohort Study

Journal of Inflammation Research2025-03-011 citations